simvastatin (simvastatin, Hanmi / simvastatin CR / Simvast CR)

✓ Approved

Hanmi Pharmaceutical · HMGCR · Small Molecule

What is simvastatin?

simvastatin is a small molecule developed by Hanmi Pharmaceutical. It is approved for therapeutic indications via oral (po).

Brand Names	simvastatin, Hanmi, simvastatin CR, Simvast CR
Company	Hanmi Pharmaceutical
Drug Class	Small Molecule
Molecular Target	HMGCR
Route	Oral (PO)
Status	Approved

simvastatin acts on 1 molecular target:

HMGCR

3-hydroxy-3-methylglutaryl-CoA reductase (LDLCQ3, LGMDR28)

Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

There are currently 597 clinical trials registered

Trial ID	Phase	Title	Status
NCT04418089	Phase 2	Combination of CAF and Simvastatin Improves Response to Neoadjuvant Chemotherapy and Increases Tumor	Completed
NCT04559841	NA	Regenerative Surgical Treatment of Peri-implantitis Using Nanobone With or Without Simvastatin: A 6-	Completed
NCT04575090	NA	7 Tesla MRI Study in Patients With Statin Related Muscle Complaints	Completed
NCT05580250	Phase 1	A Phase I, Single-Centre Study to Investigate the Safety, Tolerability and Pharmacokinetics of Singl	Withdrawn
NCT05682911	EARLY_Phase 1	Hypolipidemic, Cardioprotective and Antioxidant Effect of Zingiber Officinale L. Extract in Hyperten	Completed
NCT03375580	NA	Therapeutic Effects of Compound Zhenzhu Tiaozhi Capsules in Nonalcoholic Fatty Liver disease-a Rando	Unknown

+593 more trials available with a free account

Analyze Full Trial DataNoah can compare efficacy across trials and generate reports.

simvastatin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic Area	Condition	Phase
Metabolism and nutrition disorders	Hyperlipidaemia	✓ Approved